2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
01/13/17New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
Primary Endpoint from End of Study Analysis Presented at British Paediatric Neurology Association Annual Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with spinal muscular atrophy (SMA) compared to untreated infants. The data were prese... 
Download PDF
01/06/17Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance
Strong financial performance resulting from the continued success of pipeline programs CARLSBAD, Calif., Jan. 6, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the Company expects to significantly improve upon its 2016 financial guidance.  Ionis expects to end 2016 with pro forma net operating income in the low to mid $20 million range and more than $650 million in cash.  The Company's significantly improved financial guidance is the result of numerous ac... 
 
01/06/17Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
- Collaboration with Novartis provides near-term payments of $225 million plus potential license fees, milestone and royalty payments - Akcea retains rights to co-commercialize to lipid specialists - Deal valued at significantly over $1 billion if both drugs are licensed and successfully commercialized - Company to host conference call at 9:30 a.m. Eastern Time CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan. 6, 2017 /PRNewswire/ -- Ionis Pharmaceuticals Inc. (NASDAQ: IONS) and Akcea Ther... 
 
01/04/17Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes
- Company to present top-line results at Pipeline Update Webcast on January 5 - CARLSBAD, Calif., Jan. 4, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive data from a Phase 2 study of IONIS-GCGRRx in 79 patients with type 2 diabetes.  In this study, patients with type 2 diabetes uncontrolled on stable, maximal metformin therapy treated with IONIS-GCGRRx achieved robust and sustained, statistically significant improvements in hemoglobin A1c (HbA1c) and ...